相关实验视频

Updated: Jul 2, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

免疫特征可预测多发性骨髓瘤患者基于博特佐米布的治疗反应

Zhaoyun Liu¹, Hongli Shen¹, Mei Han¹

¹Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Heping District, Tianjin 300052, PR China; Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052 P. R. China.

International immunopharmacology

|February 20, 2024

概括

骨髓免疫细胞子集与多发性髓瘤 (MM) 阶段和治疗反应相关. 对这些淋巴细胞子集的分析可能有助于预测MM患者的预后.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

多发性骨髓瘤 (MM) 是血细胞的癌症.
了解骨髓中的免疫细胞分布对于MM的预后至关重要.
在MM的治疗疗效可以受到免疫细胞子集的影响.

研究的目的:

调查MM患者骨髓免疫细胞子集的分布.
为了将免疫细胞子集分布与临床特征和疾病病期相关联.
评估初始免疫细胞子集与治疗疗效之间的关系.

主要方法:

在186名新诊断的MM患者的骨髓淋巴细胞子集的分析,使用八色流细胞计.
免疫细胞子集与临床特征的相关性,包括疾病阶段和功能.
在四轮诱导疗法后,对152名患者的治疗反应的评估.

主要成果:

在晚期MM阶段,不成熟B细胞的百分比较低 (III阶段与III阶段相比). 第一个阶段).
在患有严重贫血的患者中,原始B细胞的百分比较低,而记忆B细胞显示出相反的趋势.
治疗后B细胞和不成熟B细胞的百分比增加与非常好的部分缓解 (VGPR) 相关联.
综合免疫子组显示治疗反应的预测值 (AUC=0.802).

结论:

骨髓中的淋巴细胞子集分析与MM分期和临床参数有关.
特定的免疫细胞亚群形状与MM的治疗反应相关.
淋巴细胞子集的分析,以及血细胞免疫类型,可以作为MM患者的预后指数.

关键词:

B 细胞 B 细胞 B 细胞流动细胞计量流动细胞计量免疫细胞是一种免疫细胞.多发性骨髓瘤是一种多发性骨髓瘤.在T细胞,T细胞.

更多相关视频

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...